Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
152
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Allogene Therapeutics Inc market cap is $231.06M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Allogene Therapeutics Inc 52 week high is $4.46 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Allogene Therapeutics Inc 52 week low is $0.65 as of November 20, 2026.
Allogene Therapeutics Inc stock price today is $0.6277.
Allogene Therapeutics Inc stock price yesterday was $0.6669.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Allogene Therapeutics Inc's P/E ratio is -1.07.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Allogene Therapeutics Inc P/B ratio is 0.5883.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Allogene Therapeutics Inc 50-day moving average is $1.32.